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Abstract WHSC2, a novel gene recently isolated within the
critical region of Wolf^Hirschhorn syndrome, is expressed in
endothelial cells. WHSC2 is downregulated by HIV-1 Tat,
whereas it is not modulated by angiogenic and pro-differentiative
molecules. WHSC2 encodes a basic polypeptide of 528 amino
acids. The in vitro translated protein shows a molecular weight of
57 kDa. WHSC2 has two nuclear translocation sequences which
actively mediate its transport to the nucleus, as shown in whsc2-
GFP-transfected NIH-3T3. We also found a helix-loop-helix
(HLH) motif in region 130^185. Since members of the HLH
family control differentiation and cell cycle progression, we
hypothesize that WHSC2 may function as a transcriptional
repressor. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The Tat protein of the human immunode¢ciency virus type
1 (HIV-1) is essential for e⁄cient HIV-1 gene expression [1].
Moreover, Tat is secreted by HIV-1-infected cells [2], and bio-
logically signi¢cant levels of Tat have been detected in the sera
of HIV-1-infected subjects [3]. Extracellular Tat binds to and
is rapidly taken up by neighboring cells [4] and can in£uence
the expression of cellular genes in both infected and unin-
fected cells [5^12].
Our interest lies in the regulation of gene expression in
endothelial cells (EC). The normal function of the endothe-
lium is impaired in HIV-1 infection. Disturbances of the local
cytokines as well as the release of Tat by infected mononu-
clear cells play a role in endothelial dysfunction. Interestingly,
in vascular EC, Tat has been shown to speci¢cally bind and
activate the Flk-1/kinase insert domain receptor (Flk/kdr)
[13], a vascular endothelial growth factor (VEGF)-A tyrosine
kinase receptor, which is a major regulator of vasculogenesis
and angiogenesis [14]. This ¢nding may explain Tat angiogen-
ic activity [15]. Indeed, Tat has been postulated to have a role
in the pathogenesis of Kaposi’s sarcoma (KS) because it is
angiogenic and it enhances the proliferative e¡ects of basic
¢broblast growth factor (bFGF) [16]. Moreover, tat transgen-
ic mice develop KS-like lesions [17]. In addition, Tat activates
ECs by stimulating the expression of E-selectin and IL-6 [18].
Because of the multiple e¡ects of Tat on EC, we isolated
di¡erentially expressed genes in Tat-treated EC to yield in-
sights into the molecular mechanisms contributing to endo-
thelial dysfunction in HIV-infected individuals, in KS and,
more generally, in angiogenesis. Here we report that Tat
downregulates the expression of whsc2 [19] in human EC.
WHSC2 has recently been isolated within the critical region
of Wolf^Hirschhorn syndrome (WHS), a multiple malforma-
tion syndrome characterized by mental and developmental
defects resulting from the deletion of the short arm of one
chromosome 4 (4p16.3) [19]. We show that WHSC2 is a nu-
clear protein expressed in various tissues and in di¡erent cell
lines. In addition, WHSC2 is not modulated by angiogenic
factors other than Tat.
2. Materials and methods
2.1. In vitro transcription and translation
WHSC2 was cloned in pBluescript and used for in vitro transcrip-
tion. WHSC2-pBluescript was incubated for 30 min at 37‡C with
proteinase K (50 Wg/ml) in 0.01 mM Tris^HCl pH 7.8 containing
0.5% SDS and 5 mM EDTA. 600 ng of proteinase K-treated DNA
were incubated with rabbit reticulocyte lysate and 0.5 Wl [35S]Met for
90 min at 30‡C. The sample was then run on 10% SDS^PAGE, ¢xed
and autoradiographed. In vitro translation of the plasmid alone did
not yield any band (not shown).
2.2. Green £uorescence protein (GFP) fusion plasmid construction
pEBFP-N1/WHSC2 was constructed by inserting HindIII and Bam-
HI cut-Whsc2 which had been obtained by PCR using Whsc2 cDNA
as template and the following oligomers: sense 5P-CCC AAG CTA
TGG CGT CCA TGC GGG AG-3P and antisense 5P-CGC GGA
TCC CCG GAC ACA TTG GTC ATG GG-3P (11). PCR reaction
was as follows: 1 min at 95‡C, 2P at 65‡C and 3P at 72‡C for 30 cycles.
The correct sequence and orientation of the construct were con¢rmed
by sequencing.
2.3. Cell culture and transfection
HUVEC-C were from ATCC and cultured in HF12 containing 10%
FCS, ECGS (150 Wg/ml) and heparin (5 U/ml) on gelatin coated
dishes. NIH-3T3 were grown in D-MEM containing 10% FCS. Cells
were seeded on glass coverslips and transiently transfected with
pEBFP-N1/Whsc2 or pEBFP-N1 alone via the calcium phosphate
coprecipitation technique [20]. 24 h after transfection cells were
washed, ¢xed in phosphate-bu¡ered saline (PBS) containing 3% para-
formaldehyde and 2% sucrose and labeled with rhodamine-conjugated
phalloidin. The signal was evaluated with a £uorescence microscope.
2.4. Western blot analysis
Antiserum was prepared using his-tag polypeptides in the N-termi-
nal region (residues 62^125) and C-terminal region (residues 364^521)
of WHSC2. Rabbits were immunized by standard procedures. IgGs
against WHSC2 were puri¢ed on a protein A Sepharose column.
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Nuclei and cytosols were fractionated as described [21]. For Western
blotting, cytosolic and nuclear fractions (50 Wg/lane) were resolved by
SDS^PAGE, transferred to nitrocellulose sheets at 150 mA for 16 h,
and probed with anti-WHSC2 IgGs (5 Wg/ml). Secondary antibodies
were labeled with horseradish peroxidase (Pierce, Rockford, IL,
USA). The SuperSignal chemiluminescence kit (Pierce) was used to
detect immunoreactive proteins.
2.5. Puri¢cation of RNA and Northern blot
Cells were treated with Tat (10 ng/ml) (Tecnogen, Italy), TPA (10
nM), HGF (10 ng/ml), FGF-2 (10 ng/ml), VEGF (10 ng/ml), IL-1 K
(10 ng/ml) for di¡erent times, rinsed with PBS and lysed in 4 M
guanidinium isothiocyanate. RNA was puri¢ed as described [20].
RNA was electrophoresed on a 1% agarose gel containing 2.2 M
formaldehyde, capillary blotted onto nylon membranes and UV-cross-
linked. WHSC2 and GAPDH were labeled with a random primer
labeling kit (Ambion). Filters were hybridized in 0.5 M sodium phos-
phate (pH 7.2) containing 7% SDS, 1 mM EDTA and 20% formamide
at 65‡C for 20 h and extensively washed at high stringency before
autoradiography.
3. Results
3.1. Characterization of WHSC2
One of the clones isolated by RNA ¢ngerprinting on EC
exposed to HIV-1 Tat [20] was denominated C4. The C4 in-
sert (600 bp) hybridized to a mRNA species of 2.4 kb (see
below). To obtain a full length clone, the initial 600 bp C4
fragment was used as a probe to screen a human fetal brain
cDNA library to obtain the full length clone. The complete
nucleotide sequence of the C4 cDNA is 1584 bp long and
contains at the 5P end a consensus translational initiation se-
quence [22]. By database similarity, we found that C4 is iden-
tical to WHSC2, independently isolated by Wright et al. dur-
ing the course of this work [19]. Wright et al. named this clone
WHSC2 since it is located in WHS critical region on chromo-
some 4, and we will attain to this denomination from now on.
WHSC2 cDNA encodes a highly hydrophilic protein of 528
amino acids (pI 9.8). Indeed, by in vitro transcription^trans-
lation, we could detect a single band with a molecular weight
of 57 kDa, as predicted by computational analysis (Fig. 1).
WHSC2 was expressed in all the human tissues examined
and was most abundant in the heart and placenta (Fig. 2A).
WHSC2 was also detected in all the human cell lines exam-
ined (Fig. 2B).
3.2. WHSC2 expression in human EC exposed to angiogenic
factors
The downregulation of WHSC2 by Tat detected by RNA
¢ngerprinting was con¢rmed by Northern blot analysis. Tat
(10 ng/ml) decreased WHSC2 RNA to almost undetectable
levels within 4 h and up to 24 h (Fig. 3). Because Tat has
an angiogenic activity, we evaluated whether prototypic an-
giogenic factors ^ such as VEGF, FGF-2 and HGF-modu-
lated WHSC2 expression. While these three polypeptides
stimulated endothelial proliferation, they did not modula-
Fig. 1. In vitro translation of WHSC2. WHSC2 cloned in pBlue-
script was in vitro transcribed and translated as described. The sam-
ple was then run on a 10% SDS^PAGE and autoradiographed.
Fig. 2. Tissue distribution of WHSC2. A: Multiple human adult tissue Northern blot was purchased from Clontech. Northern blot was per-
formed at high stringency using the human WHSC2 cDNA probe. Hybridization with L actin indicates that similar amounts of RNA were
used per lane; as indicated by the manufacturers, heart and skeletal muscle contain two forms of L actin, 2.0 and 1.8 kb. Lanes: 1, heart;
2, brain; 3, placenta; 4, lung; 5, liver; 6, muscle; 7, kidney; 8, pancreas. B: Multiple human cancer cell lines Northern blot was from Clon-
tech. Northern blot was performed as described above. Lanes: 1, promyelocytic leukemia HL-60; 2, HeLa; 3, chronic myelogenous leukemia
K562; 4, lymphoblastic leukemia MOLT-4; 5, Burkitt’s lymphoma Raji; 5, colorectal carcinoma SW480; 7, lung carcinoma A459; 8, melano-
ma G361.
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teWHSC2 RNA (Fig. 4A). We then asked whether WHSC2
could be modulated in the di¡erentiation of EC [23]. Since
interleukin 1 and the phorbol ester TPA promote endothelial
di¡erentiation [23], we treated HUVEC with IL-1 and TPA
for di¡erent times. Fig. 4B shows that no modulation of
WHSC2 RNA occurs under these experimental conditions.
3.3. WHSC2 is a nuclear protein
By computational analysis, we found that WHSC2 pos-
sesses two potential nuclear localization sequences (NLS).
The NLSs start at amino acid 166 and 272, and are composed
by a basic amino acid cluster which is homologous to the NLS
of simian virus 40-encoded large tumor antigen [24]. To eval-
uate whether the NLSs drive WHSC2 to the nucleus, we fused
WHSC2 in frame with GFP and transiently transfected the
construct in NIH-3T3 cells. As shown in Fig. 5A, the fusion
protein is localized in the nucleus of transfected cells, while
GFP alone is distributed throughout the cytoplasm. We also
examined the cellular distribution of WHSC2 in HUVEC
after cell fractionation. Western blot analysis using anti-
WHSC2 IgGs showed that WHSC2 was localized in the nu-
cleus (Fig. 5B). Controls on the cytosolic and nuclear frac-
tions were performed with anti-LDH and anti-SP1, respec-
tively (not shown).
Prediction of the secondary structure by the Chou^Fasman
method has shown that WHSC2 has a putative helix-loop-
helix (HLH) structural motif between amino acid 130 and
185 (not shown). This motif has been aligned and compared
with the HLH domain of other members of the family, among
which c-myc, MyoD and Id (Fig. 6). Fig. 6 also reports the
putative HLH domain, where conserved amino acids are
boxed and apolar residues indicated with an asterisk.
4. Discussion
WHSC2 has been recently isolated within the WHS critical
region and hypothesized to play a role in the phenotype of the
WHS, a syndrome characterized by a constellation of symp-
toms including growth de¢ciency, severe mental retardation,
facial, skeletal and heart defects [19]. Here we show that
WHSC2 is expressed in all the human tissues and cell lines
tested. The ubiquitous expression of WHSC2 may explain, at
least in part, the severe phenotype observed in patients with a
deletion in the short arm of chromosome 4 as described in
WHS [19]. The development of mouse strains with the
WHSC2 deletion may identify a role for this gene in WHS.
Human EC express rather high levels of WHSC2 RNA.
Tat, which transactivates both viral and host genes [1,5^12],
downregulates WHSC2, while angiogenic factors and pro-dif-
ferentiative molecules have no e¡ect on WHSC2 RNA levels.
The di¡erent response to VEGF and Tat is surprising since
Tat has been shown to speci¢cally bind and activate the
VEGF-A receptor, namely Flk-1/kdr [13]. Since the extracel-
lular matrix plays an important role in presenting growth
factors to their cognate receptors [25], it is conceivable that
a particular microenvironment is necessary for Tat to interact
with Flk-1/kdr. Alternatively, since it is known that Tat is
taken up by the cells and then transported to the nucleus
Fig. 3. Modulation of WHSC2 expression by Tat in human EC.
Con£uent cultures of HUVEC were exposed to 10 ng/ml Tat for
1, 4 and 24 h. Total RNA (10 Wg/lane) was analyzed by Northern
blot as described. The blot was rehybridized to GAPDH to verify
equal amounts of RNA loading among the lanes.
Fig. 4. Modulation of WHSC2 expression in human EC. Con£uent cultures of HUVEC were exposed to 10 ng/ml HGF, FGF-2 and VEGF
(A) or with TPA (10 nM) and IL-1 (10 ng/ml)(B) for 1, 4 and 24 h. Total RNA (10 Wg/lane) was analyzed by Northern blot as described. The
blot was rehybridized to GAPDH to verify equal amounts of RNA loading among the lanes.
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[26], it is reasonable to propose that Tat regulates WHSC2
expression by directly acting in the nucleus.
WHSC2 encodes a 528 amino acid protein which was in
vitro translated and migrated with a molecular mass of 57
kDa. Interestingly, WHSC2 possesses two putative NLSs.
These basic sequences are recognized by NLS-binding pro-
teins that function as adapter molecules of the nuclear trans-
port machinery [24]. The NLSs we have identi¢ed in WHSC2
are similar to the prototypical NLS found in simian virus
40 large tumor antigen in their high content of basic amino
acids [24] and are able to translocate GFP to the nucleus of
transiently transfected 3T3. Moreover, after cell fractiona-
tion, we detected WHSC2 mainly in the nuclear fraction of
HUVEC. We therefore conclude that WHSC2 is a nuclear
protein.
On the basis of a careful sequence analysis, we propose that
WHSC2 contains an HLH motif in the N-terminus region.
Basic HLH transcription factors regulate cell-type-speci¢c
gene expression and the expression of cell cycle regulatory
genes [27]. Proteins lacking the basic DNA binding domain
upstream from the HLH ^ such as Id ^ dimerize with basic
HLH [28], thus behaving as transcriptional repressors by pre-
venting the basic HLH proteins from binding DNA [28].
However, an alternative mechanisms of action of WHSC2
can be proposed. Since WHSC2 is a member of the negative
elongation factor (NELF) protein complex [29], which
Fig. 5. Nuclear localization of WHSC2. A: NIH-3T3 were transfected with GFP (pEBFP-N1) or WHSC2 fused to GFP (pEBFP-N1-whsc2).
After labeling the cytoskeleton with rhodamine-conjugated phalloidin, cells were observed with a £uorescence microscope (60U) and photo-
graphed. B: Western blot analysis was performed on the cytosolic and nuclear fractions of HUVEC utilizing anti-WHSC2 IgGs. C: cytosol;
N: nucleus.
Fig. 6. Sequence comparison between the putative HLH domain of WHSC2 and other members of the HLH family. The putative HLH motif
of WHSC2 was compared with MyoD, c-myc and Id. Conserved residues are boxed and reported below together with apolar amino acids,
which are indicated with an asterisk, to identify the HLH region.
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strongly represses polII elongation, WHSC2 may exert its
control on gene expression by modulating the elongation
step of transcription.
Further experiments are required to elucidate whether
WHSC2 represses transcription and which mechanisms are
involved.
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